Biopharmaceuticals

The biopharmaceutical division develops, produces and markets prescription drugs for the therapeutic areas of Neurodegenerative Diseases, Oncology, Fertility, Endocrinology, CardioMetabolic Care and General Medicine.

Neurodegenerative diseases

Our goal is to offer people living with neurodegenerative diseases, such as multiple sclerosis, therapies that contribute significantly to the quality of life and meet patients’ needs.

Oncology

In oncology, we are focusing on therapeutic options that systematically target the tumor. The key is finding the right combination. This refers both to the targets of a therapy in the disease process and to the combination possibilities with standard therapies such as radiation or chemotherapy.

Fertility

For fertility treatment, we offer hormones for every stage of the reproductive cycle – from follicular development to early pregnancy.

Endocrinology

We are committed to the treatment and research of growth hormone deficiency, the rare disorder phenylketonuria (PKU) and other metabolic disorders.

CardioMetabolic Care

We offer a comprehensive range of therapeutic options for cardiovascular diseases, diabetes and thyroid diseases, thus making a significant contribution to effective treatment of often complex symptoms.

 

Biopharmaceuticals

Our biopharmaceutical division is pursuing activities in selected indications for highly specialized therapeutic areas mainly treated by specialists. The portfolio includes leading biopharmaceutical drugs that benefit patients who suffer from colorectal cancer, head and neck tumors or multiple sclerosis. In addition, we offer therapies to treat infertility, growth disorders, cardiovascular diseases, diabetes and thyroid diseases
Research and development are focused on the fields of oncology, immuno-oncology, neurodegenerative diseases, fertility, endocrinology and biosimilars.
Key products by therapeutic area
Therapeutic Area  Key Products
Oncology
  • Erbitux® (solid tumors)
  • UFT®
Neurodegenerative Diseases
Fertility
Endocrinology
CardioMetabolic Care
  • Glucophage® franchise (type 2 diabetes)
  • Concor® franchise (cardiovascular diseases)
  • Euthyrox® (thyroid diseases)

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.
 

DIVISION SITE

www.emdserono.com

CLINICAL TRIALS

Clinical Trials
For information on clinical trials currently being conducted in the framework of our development projects, please click here.
 
  
Read more on M - The Explorer Magazine

Living with pancreatic cancer

Pancreatic cancer is one of the most aggressive types of cancer. In a new approach to cancer treatment, chemotherapy is combined with the active ingredient TH-302.

Read more on M - The Explorer Magazine
Read more on M - The Explorer Magazine

OLEDs: impressive innovations

OLED displays can be inexpensively manufactured using inkjet technology. AUO in Taiwan, one of the leading display suppliers, is aiming to make this process suitable for mass production.

Read more on M - The Explorer Magazine
Read more on M - The Explorer Magazine

Keeping insects away with a biological repellent

With its active ingredient IR3535, EMD offers a nature inspired insect repellent that provides effective protecion and maximum safety for people and animals.

Read more on M - The Explorer Magazine